重庆医学2025，Vol.54Issue(7)：1560-1565,6.DOI:10.3969/j.issn.1671-8348.2025.07.006
血脂康联合PCSK9抑制剂治疗冠心病的临床效果及安全性
Study on the efficacy and safety of Xuezhikang combined with PCSK9 inhibitor in the treatment of coronary heart disease
摘要
Abstract
Objective To investigate the lipid-lowering efficacy and safety of Xuezhikang combined with PCSK9 inhibitor in patients with coronary heart disease.Methods A total of 102 patients with coronary heart disease hospitalized in Jiangxi Provincial People's Hospital from June 2023 to November 2024 were enrolled in this study and randomly divided into a control group(50 cases)and an experimental group(52 cases).The control group received basic medication for secondary prevention of coronary heart disease,while the experi-mental group received Xuezhikang combined with PCSK9 inhibitor in addition to the basic medication.After 6 months of treatment,blood lipid indicators,liver function indicators,kidney function indicators,incidence of major adverse cardiovascular events(MACE),and incidence of adverse drug reactions were observed.Results After treatment,LDL-C,TC,AST,and ALT levels decreased in both groups compared with before treatment.The experimental group showed significantly lower levels of these indicators than the control group,with statistically significant differences(P<0.05).Both groups had one case of adverse drug reaction each,showing no statistically significant difference(P>0.05).The MACE incidence was higher in the control group than in the experimental group(18.0%vs.3.8%,P<0.05).The lipid goal achievement rate was low-er in the control group than in the experimental group(44.0%vs.73.1%,P<0.05).Conclusion The com-bination of Xuezhikang and PCSK9 inhibitors demonstrates definite clinical efficacy in coronary heart disease patients,reduces MACE risk,and improves lipid goal achievement rates.关键词
冠心病/PCSK9抑制剂/血脂康/低密度脂蛋白-胆固醇/主要不良心血管事件Key words
coronary heart disease/PCSK9 inhibitor/Xuezhikang/low-density lipoprotein cholesterol/major adverse cardiovascular events分类
医药卫生引用本文复制引用
刘子铭,贺晓仔,曾洪,王晶,黄媛,常智堂..血脂康联合PCSK9抑制剂治疗冠心病的临床效果及安全性[J].重庆医学,2025,54(7):1560-1565,6.基金项目
江西省中医药管理局科技计划项目(2023B0118). （2023B0118）
